Left-eyesterdayA couple of fine points. Prochymal and...

Left-eyesterday

A couple of fine points. Prochymal and remestemcel-L are the "same", but keep in mind that in 2016 Mesoblast acquired exclusive rights to a process called "ex vivo fucosylation", said to significantly improve a cell's ability to home to problem areas that need immune modulation.

So, we could say remestemcel-L is a "new and improved" Prochymal, and that point should be kept in mind when evaluating Prochymal trial data.

My understanding is that the brand name "Ryoncil" is reserved for remestemcel-L use for the GvHD indication only. Marketing for ARDS will probably occur under a different brand name, still to be announced. Some of the older clinical trials referred to "MSC-100-IV", which is another term for Prochymal and remestemcel-L. Mesoblast is also developing MPC's, mesenchymal precursor cells.. Collectively MPC's along with MSC's like remestemcel-L, the entire product line is referred to as Mesenchymal Lineage Cells, MLC's.

Mesoblast has foundational patents covering mesenchymal cells from any source at any age, which is why PSTI and ATHX sometimes quake and do strange things, like using cells so immature they may not be efficacious, or calling cells "mesenchymal-like", whatever that means.

A few good points regarding our new product Ryoncil thanking to @LeftYahoo.

Glta